CRIS Current Research Information System

CURTI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.305
AS - Asia 5.507
EU - Europa 4.647
AF - Africa 431
SA - Sud America 323
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 7
Totale 17.240
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.234
CN - Cina 1.664
SG - Singapore 1.608
GB - Regno Unito 1.069
VN - Vietnam 1.016
SE - Svezia 814
IT - Italia 810
DE - Germania 554
HK - Hong Kong 372
IN - India 306
KR - Corea 237
BR - Brasile 236
NL - Olanda 224
RU - Federazione Russa 210
IE - Irlanda 171
FR - Francia 150
UA - Ucraina 142
CI - Costa d'Avorio 110
TG - Togo 103
ZA - Sudafrica 82
FI - Finlandia 81
BG - Bulgaria 70
JO - Giordania 69
CH - Svizzera 63
SC - Seychelles 63
GR - Grecia 61
JP - Giappone 60
EE - Estonia 58
CA - Canada 50
NG - Nigeria 46
AR - Argentina 44
BE - Belgio 40
ID - Indonesia 37
TR - Turchia 35
AT - Austria 32
IR - Iran 29
ES - Italia 27
PL - Polonia 23
EU - Europa 18
MX - Messico 14
BD - Bangladesh 13
EC - Ecuador 13
LT - Lituania 10
PH - Filippine 10
EG - Egitto 9
CL - Cile 8
CO - Colombia 7
LB - Libano 7
MA - Marocco 7
IQ - Iraq 6
MY - Malesia 6
PT - Portogallo 6
RO - Romania 6
CZ - Repubblica Ceca 5
PE - Perù 5
AU - Australia 4
HR - Croazia 4
QA - Qatar 4
TH - Thailandia 4
UY - Uruguay 4
KG - Kirghizistan 3
KZ - Kazakistan 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
RS - Serbia 3
TW - Taiwan 3
UZ - Uzbekistan 3
VE - Venezuela 3
AL - Albania 2
DZ - Algeria 2
HU - Ungheria 2
IL - Israele 2
KE - Kenya 2
LI - Liechtenstein 2
MU - Mauritius 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
GY - Guiana 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MK - Macedonia 1
MM - Myanmar 1
PA - Panama 1
SA - Arabia Saudita 1
SN - Senegal 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 17.238
Salva come PNG Salva come JPEG
Città #
Singapore 1.076
Southend 951
Ashburn 756
Chandler 642
Fairfield 599
Hefei 522
Hong Kong 369
Woodbridge 302
Wilmington 273
Ann Arbor 270
Seattle 250
Houston 248
Santa Clara 244
Ho Chi Minh City 232
Seoul 224
Beijing 212
Cambridge 203
Princeton 203
Dong Ket 202
Hanoi 193
Dublin 171
Dallas 158
Bologna 154
Boardman 140
Abidjan 110
Lomé 103
Westminster 86
Los Angeles 81
New York 80
Nanjing 79
Padova 72
Amman 69
Sofia 68
Jacksonville 62
Milan 57
Tokyo 56
Helsinki 53
Bern 52
Berlin 48
Buffalo 48
Bremen 47
Redondo Beach 46
Frankfurt am Main 45
Jinan 45
Bengaluru 44
Hyderabad 42
Munich 42
San Diego 41
Brussels 40
Shenyang 39
Turin 38
Tianjin 36
Medford 32
Saint Petersburg 32
São Paulo 30
Abeokuta 29
Rome 28
Zhengzhou 28
Florence 27
Nanchang 26
Jakarta 25
Hebei 24
Redmond 23
Guangzhou 21
Haiphong 21
Istanbul 21
Shanghai 20
Falkenstein 19
Redwood City 19
Toronto 19
Jiaxing 18
Phoenix 18
Tongling 18
Changsha 17
Da Nang 17
Biên Hòa 16
Lappeenranta 16
London 16
Ninh Bình 16
Nuremberg 16
Quận Bình Thạnh 16
Vienna 16
Atlanta 15
Chicago 15
Mülheim 15
Norwalk 15
San Francisco 15
Des Moines 14
Grafing 13
Hangzhou 13
Mahé 13
Boston 12
Falls Church 12
Lanzhou 12
Washington 12
Wuhan 12
Yubileyny 12
Amsterdam 11
Brooklyn 11
Can Tho 11
Totale 11.100
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 313
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia 309
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 305
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 284
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 255
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 240
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 237
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 225
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 224
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 218
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 212
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 204
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 202
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 201
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 201
A case report of acute myeloid leukemia and neurofibromatosis 1 196
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 194
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 194
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 194
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 193
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 191
ATP release from chemotherapy-treated dying leukemia cells Elicits an immune suppressive effect by increasing regulatory T cells and Tolerogenic dendritic cells 190
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 187
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 187
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 184
Flow cytometry analysis of T-cell subsets in cerebrospinal fluid of narcolepsy type 1 patients with long-lasting disease 181
Immunosenescence and immunotherapy in elderly acute myeloid leukemia patients: Time for a biology-driven approach 170
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 168
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 166
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 166
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 165
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia 164
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 163
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 163
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 161
The more, the better: "Do the right thing" for natural killer immunotherapy in acute myeloid leukemia 161
Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. 161
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 161
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 159
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 158
Dendritic cell differentiation. 158
Extracellular ATP exerts opposite effects on activated and regulatory CD4 + T cells via purinergic P2 receptor activation 158
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 158
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. 157
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 156
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 156
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 152
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 151
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 151
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response 151
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy 151
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. 150
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 150
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 150
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 149
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 149
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 149
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 149
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 148
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 148
Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells 148
Corrigendum: Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells (Front. Oncol, (2020), 10, (1225), 10.3389/fonc.2020.01225) 147
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. 146
Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients 144
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 144
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 144
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 144
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 140
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 137
Immune characterization in Narcolepsy Type 1. 137
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 134
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 132
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 131
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 129
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 126
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 126
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 126
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 124
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 123
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 123
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 121
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 118
More ADO about IDO: GVHD. 118
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 117
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML 116
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms 115
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 114
Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade 114
Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells 113
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 112
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 109
The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia 109
null 107
A phase I study of Tipifarnib and Bortezomib in the treatment of poor risk adult acute myeloid leukemia (AML) 107
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 106
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study 105
FLUDARABINE, CYTARABINE, IDARUBICIN AND ETOPOSIDE (FLAIE) SCHEDULE IS SAFE AND ACTIVE FOR YOUNG PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF A MULTICENTRIC PHASE III ITALIAN STUDY 105
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 104
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 102
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 101
Totale 15.966
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.782
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.782
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021864 0 0 0 0 0 82 34 108 135 87 42 376
2021/20222.233 153 67 131 226 193 128 45 168 127 191 415 389
2022/20232.587 331 401 124 321 188 201 81 149 421 50 170 150
2023/2024756 49 110 41 99 57 170 39 35 27 38 66 25
2024/20253.023 151 372 225 206 407 150 196 95 74 300 217 630
2025/20264.342 1.022 1.103 680 673 706 158 0 0 0 0 0 0
Totale 17.582